United Kingdom Cannabis Law

The United Kingdom legalized medical cannabis prescriptions in November 2018 under Schedule 2 of the Misuse of Drugs Regulations, following the high-profile cases of Alfie Dingley and Billy Caldwell. The UK's medical cannabis market — despite being prescription-only — has grown significantly, with specialist clinics serving tens of thousands of patients. Post-Brexit, the UK's regulatory framework operates independently of EU drug policy, creating a distinctive hybrid environment.

Bob Hoban has advised US and Canadian operators on UK market entry strategy, Home Office cultivation and processing license applications, and the regulatory pathway for international cannabis companies seeking to supply the UK market. The MHRA's position on cannabis-based medicinal products (CBMPs) differs from the EU's EMEA approach, requiring separate regulatory assessment for the UK market.

Key advisory areas include Home Office Schedule 1 to Schedule 2 reclassification implications, the Medicines and Healthcare products Regulatory Agency (MHRA) CBMP pathway, GCP/GMP compliance for UK supply chain operators, and M&A opportunities in the rapidly growing UK cannabis clinic and distribution sector.